SOUTHLAKE, Texas, April 25, 2025 /PRNewswire/ -- Renibus Therapeutics ® ("Renibus"), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardiac, renal, and ...
- Renibus recently completed enrollment in a Phase 3 pivotal trial PROTECT to reduce the risk of post-operative complications and improve outcomes following cardiac surgery - RBT-1 is a single-dose, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback